Completion of nodal dissection in cutaneous melanoma with metastatic sentinel nodes: Prognostic impact in a population-based cohort study

Table 4 Multivariate regressions of overall and melanoma-specific survival for stage III CM patients with metastatic (axillary or inguinal) SLNB

	Overall survival			Melanoma-specific survival
	HR	95% CI	P value	sHR	95% CI	P value
Age	1.04	1.02–1.06	<0.001	1.04	1.01–1.06	0.001
pN-value
N3 vs. N1-2	4.95	2.47–9.92	<0.001	6.33	2.92-1.37	<0.001
CLND
T1 Yes, inadequate vs. No	1.18	0.24–5.79	0.840	2.80	0.48–16.41	0.255
T1 Yes, adequate vs. No	0.42	0.70–1.02	0.055	0.51	0.18–1.44	0.202
T2 Yes, inadequate vs. No	1.18	0.28–5.07	0.819	1.77	0.34–9.20	0.496
T2 Yes, adequate vs. No	1.52	0.64–3.59	0.344	2.12	0.68–6.68	0.198
Anatomical site
Upper limbs vs. Hands/Feet	0.83	0.29–2.41	0.734	1.21	0.41–3.55	0.724
Lower limbs vs. Hands/Feet	0.85	0.36–2.05	0.722	0.96	0.37–2.54	0.941
Head vs. Hands/Feet	0.38	0.08–1.85	0.228	0.37	0.05–2.91	0.345
Trunk vs. Hands/Feet	1.02	0.47–2.22	0.954	0.98	0.45–2.12	0.951
Missing vs. Hands/Feet	0.52	0.05–6.09	0.606	<0.01	910^(−10)−610^(−8)	<0.001
Histotype
Nodular vs. Superficial Spreading	0.70	0.41–1.20	0.190	0.61	0.34–1.12	0.111
Other vs. Superficial Spreading	0.79	0.23–2.60	0.697	1.32	0.49–3.60	0.583
Not specified vs. Superficial Spreading	0.58	0.22–1.57	0.287	0.50	0.15–1.65	0.255

HR hazard ratio, sHR sub-distribution hazard ratio, CI confidence interval, t1 from 0 to 770 days from diagnosis, t2 more than 770 days from diagnosis
Bold: statistically significant value (p< 0.005)

ISSN: 1477-7819